TG Therapeutics 2026 Annual Meeting Results: Key Details for Investors
Summary of Key Points
- Annual Meeting Date: June 11, 2026 (held online at 9:30 a.m. Eastern Time)
- Shareholder Participation: 113,003,414 shares represented (73.81% of 153,093,879 outstanding shares), constituting a quorum
- Proposals: Three proposals voted; all approved except Proposal 3
- Directors Elected: Six directors elected for terms until the 2027 annual meeting
- Auditor Ratified: KPMG LLP ratified as independent registered public accounting firm for fiscal year 2026
- Executive Compensation: Shareholders rejected the advisory vote to approve the compensation of named executive officers
- Price Sensitivity: Rejection of executive compensation proposal may be viewed negatively by the market
Detailed Results and Analysis
Proposal 1: Election of Directors
Six directors were elected to serve until the 2027 annual meeting. Here are the vote tallies for each nominee:
| Director | Votes For | % Voted For | Votes Withheld | % Voted Withheld | Broker Non-Votes |
|---|---|---|---|---|---|
| Michael S. Weiss | 72,172,630 | 11.37% | 31,570,505 | ? | ? |
| Laurence N. Charney | 68,135,448 | 83.67% | 13,297,461 | 16.33% | 31,570,505 |
| Yann Echelard | 78.57% | 17,453,374 | 21.43% | 31,570,505 | |
| Sagar Lonial, MD | 44,666,544 | 54.85% | 36,766,365 | 45.15% | 31,570,505 |
Note: All director nominees were elected, affirming stable governance and continuity of leadership.
Proposal 2: Ratification of Independent Auditor
Shareholders approved the ratification of KPMG LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026:
- Total Votes For: 112,329,330
- Total Votes Against: 531,758
- Abstentions: 142,326
- Broker Non-Votes: None
This result signals broad confidence in the Company’s financial oversight and reporting practices.
Proposal 3: Advisory Vote on Executive Compensation (FAILED)
The advisory vote to approve the compensation of TG Therapeutics’ named executive officers was NOT approved by shareholders:
- Total Votes For: 31,905,837
- Total Votes Against: 48,858,169
- Abstentions: 668,903
- Broker Non-Votes: 31,570,505
Implications:
- This result could be viewed as a significant signal of shareholder dissatisfaction with current executive pay policies.
- Such rejection may prompt a review of compensation practices and could have reputational or governance ramifications.
- Potential for increased scrutiny, activism, or pressure for change in leadership or compensation structure.
Other Notable Information
- The company is not classified as an “emerging growth company” under SEC rules.
- No written communications, soliciting materials, or tender offer-related filings were indicated.
- Common stock is traded under the symbol TGTX on the NASDAQ Capital Market.
- Business address: 3020 Carrington Mill Blvd, Suite 475, Morrisville, NC 27560. Phone: (212) 554-4484.
Potential Price Sensitive Factors
- Rejection of executive compensation proposal is the most notable price-sensitive event. This could lead to negative sentiment or calls for changes in leadership or compensation policy.
- Strong participation and approval of auditor reaffirm financial stability but are not typically price-moving unless auditor change or issues arise.
- All other proposals passed, indicating overall shareholder confidence except for executive pay.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making any investment decisions. The information herein is based on official SEC filings and is believed to be accurate at the time of publication, but no warranty is given for completeness or accuracy.
